Trends
The factsheet collates data published in the public registry to present them in a more concise and accessible form. The fields of information for analysis are CTR-I ID, brief study title, study status, trial location, ethics committee details, sponsor, disease condition, trial start date, DCGI approval, and study type. Certain text-heavy fields like exclusion and inclusion criteria are left out.
The second factsheet published in the April-June 2010 issue of this journal reflects the effect of the DCGI's mandate; the number of trials registered increased to 689 in the six month period from June 15 2009 to Dec 31 2009. That is, the sixmonthly period since the mandate came into effect shows registration of twice as many trials as the number voluntarily registered over a two-year period from the launch of the registry (5).
A large number of registered studies (292) are phase 3 studies. 128 studies are from phase 2 and 41 studies belong to phase 1 (Fig.1) . Contrary to the assumption that India lacks a culture of phase 4 studies, 85 registered studies belong to phase 4. Some studies do not have clearly defined phases: these include 20 phase1/2 studies, 42 phase2/3 studies, and 16 phase 3/4 studies. A large number of studies (436) Although the number of registered trials has substantially increased since the DCGI mandate, the two published factsheets have similar patterns. For example, in Factsheet 2, an overwhelming majority of trials registered in the register are drug trials. 501 of 689 registered trials are drug trials. Other types of trials are those related to devices, procedures, dietary supplements, radiation, biological, and behavioural trials. The most prominent disease categories continue to be neoplasms (110), endocrine, nutritional and metabolic diseases (77), diseases of the circulatory system (73) and lastly bacterial infections, intestinal infectious diseases and sexually transmitted diseases (69) (Fig. 2) . Approximately one-third of the trials registered on CTR-I (219/689) are placebo-controlled, while another one-third (222/689) comprise active controlled trials (Fig.3) . This pattern is reflected in the first factsheet as well.
Conclusion
The recent mandate to register clinical trials has increased accountability and transparency in the system. However, it is not known whether strict and timely action will be taken in cases of unregistered, illicit trials.
The registry allows for updates to trial information, but these updates cannot be tracked. Another primary register, clinicaltrials.gov , records and archives the "history of changes" made to each trial from the date of its registration. Clinicaltrials. gov also provides space for enlisting publications and uploading trial reports. No such provision has been made on CTR-I.
Only CTR-I requires the names of all ethics committees, approval status, site addresses and names of contact persons for each site. This helps in conforming to the ethical standards set by the ICMR.
Almost all trials registered on CTR-I are primarily conducted in India, restricting the impact of CTR-I to the Indian context. I  1  7  33  II  2  6  22  45  53  III  2  22  39  90  139  IV  7  8  27 
